Figure 1: Pneumococcal Vaccine Recommendations for Adults 19-64 Years Old (online only)

The Medical Letter on Drugs and Therapeutics

ONLINE
ONLY
ARTICLE

October 14, 2024

View Complete Issue Table of Contents 2019

Download PDF: US English

Disclosures & Objectives Disclosures & Objectives

Show Related Terms Hide Related Terms

View Complete Issue

Send Article Feedback

Med Lett Drugs Ther. 2024 Oct 14;66(1713):e163 doi:10.58347/tml.2024.1713f

Disclosures

Principal Faculty

Mark Abramowicz, M.D., President has disclosed no relevant financial relationships.
Jean-Marie Pflomm, Pharm.D., Editor in Chief has disclosed no relevant financial relationships.

Objective(s)

Upon completion of this activity, the participant will be able to:

Review the efficacy and safety of Capvaxive, a 21-valent pneumococcal conjugate vaccine, for prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults.

Select a term to see related articles PCV13 Pneumococcal vaccine PPSV23 vaccines

Superseded by The Medical Letter "Comparison Table: Pneumococcal Vaccine Recommendations for Adults 19-49 Years Old (online only)" - Issue 1734, August 4, 2025

View Figure 1: Pneumococcal Vaccine Recommendations for Adults 19-64 Years Old

Download PDF: US English

The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

This article has been freely provided.